Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Gilead Sciences
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04060147CT.gov Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis | — | Terminated | — | — | — |
NCT03890120CT.gov Study of Cilofexor in Adults With Primary Sclerosing Cholangitis | — | Terminated | — | — | — |
NCT02943460CT.gov Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis | — | Completed | — | — | — |
NCT02808312CT.gov Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Sclerosing Cholangitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cilofexor (this asset) | Gilead Sciences | P3 | B · 59 |
| Vancomycin | Tampere University Hospital | P4 | BB |
| Ursodeoxycholic Acid | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Aldafermin | NGM Biopharmaceuticals, Inc | P2/3 | B |
| Elafibranor | Ipsen | P3 | B |
| htd1801 | HighTide Biopharma Pty Ltd | P2 | B |
| CM-101 CCL24 BLOCKING MONOCLONAL ANTIBODY | ChemomAb Ltd. | P2 | B |
| Tretinoin | Yale University | P2 | B |
| Fenofibrate | Mayo Clinic | P2 | B |
+42 more in the Primary Sclerosing Cholangitis cohort
Other indications for Cilofexor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | P2 | B · 63 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P2 | CCC · 53 |
| Primary Biliary Cholangitis | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cilofexor in Primary Sclerosing Cholangitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cilofexor-primary-sclerosing-cholangitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →